Abstract:Microneedle patches coated with solid-state influenza vaccine have been developed to improve vaccine efficacy and patient coverage. However, dip coating microneedles with influenza vaccine can reduce antigen activity. In this study, we sought to determine the experimental factors and mechanistic pathways by which inactivated influenza vaccine can lose activity, as well as develop and assess improved microneedle coating formulations that protect the antigen from activity loss. After coating microneedles using a standard vaccine formulation, the stability of influenza vaccine was reduced to just 2%, as measured by hemagglutination activity. The presence of carboxymethylcellulose, which was added to increase viscosity of the coating formulation, was shown to contribute to vaccine activity loss. After screening a panel of candidate stabilizers, the addition of trehalose to the coating formulation was found to protect the antigen and retain 48–82% antigen activity for all three major strains of seasonal influenza: H1N1, H3N2 and B. Influenza vaccine coated in this way also exhibited thermal stability, such that activity loss was independent of temperature over the range of 4–37°C for 24h. Dynamic light scattering measurements showed that antigen activity loss was associated with virus particle aggregation, and that stabilization using trehalose largely blocked this aggregation. Finally, microneedles using an optimized vaccine coating formulation were applied to the skin to vaccinate mice. Microneedle vaccination induced robust systemic and functional antibodies and provided complete protection against lethal challenge infection similar to conventional intramuscular injection. Overall, these results show that antigen activity loss during microneedle coating can be largely prevented through optimized formulation and that stabilized microneedle patches can be used for effective vaccination.

Intradermal Administration of Influenza Vaccine with Trehalose and Pullulan-Based Dissolving Microneedle Arrays.

Influenza Immunization with Trehalose-Stabilized Virus-Like Particle Vaccine Using Microneedles.

Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization

Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin.

Dissolving Microneedle Arrays As a Hepatitis B Vaccine Delivery System Adjuvanted by APC-Targeted Poly (Lactic-Co-glycolic Acid) (PLGA) Nanoparticles

Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity

Enhanced Memory Responses to Seasonal H1n1 Influenza Vaccination of the Skin with the Use of Vaccine-Coated Microneedles

Implantable microneedles with an immune-boosting function for effective intradermal influenza vaccination

Coated Porous Microneedles for Effective Intradermal Immunization with Split Influenza Vaccine

Intradermal Vaccination with PLGA Nanoparticles via Dissolving Microneedles and Classical Injection Needles

Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch

Egg microneedles for transdermal vaccination of inactivated influenza virus

Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles

Stability Kinetics of Influenza Vaccine Coated onto Microneedles During Drying and Storage

Stability of Influenza Vaccine Coated Onto Microneedles.

Dissolving Microneedle Arrays with Optimized Needle Geometry for Transcutaneous Immunization

Cutaneous immunization: an evolving paradigm in influenza vaccines.

Improved Influenza Vaccination in the Skin Using Vaccine Coated Microneedles

Microneedle Delivery of an M2e-TLR5 Ligand Fusion Protein to Skin Confers Broadly Cross-Protective Influenza Immunity.

Microneedle Delivery of Trivalent Influenza Vaccine to the Skin Induces Long-Term Cross-Protection